IP Library Granted Patent US 7,842,677
Granted Patent B2
US 7,842,677 · App. 10/487,841 · Granted Nov 30, 2010

Synthetic ganglioside derivatives and compositions thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,842,677
App. No.
10/487,841
Granted
Nov 30, 2010
Kind
B2
Abstract

Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

Claims (27)

1. A synthetic compound having a formula selected from the group consisting of (Va), (Vb), (Vc) and (Vd):

wherein the saccharide portion is selected from the group consisting of

X is NR 1 R 2 ;

Y is —OH;

Z is O;

each R 1 and R 2 are independently selected from the group consisting of —C(=M)R 3 , and —C(=M)-p-R 3 ;

wherein M and p are independently selected from O, NR 4 and S;

R 3 is H, alkyl, arylalkyl, haloalkyl, aryl, heteroaryl, or heteroalkyl;

R 4 is H, alkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, or haloalkyl;

R 6 is H;

R 6′ is —NR 9 R 10 ;

R 6 ″ is H;

R 7 and R 8 are independently H, and aryl, where, R 7 and R 8 are optionally substituted with at least one group selected from the group consisting of halo, haloalkyl, alkoxy, and thiohaloalkyl;

R 7′ and R 8′ are independently H, alkenyl, —C(═O)NR 9 R 10 , aryl, heteroaryl, or a linked bicyclic mixture of aryl and heteroaryl, where R 7′ and R 8′ are optionally substituted with at least one group selected from the group consisting of halo, haloalkyl, alkoxy, and thiohaloalkyl;

R 9 , R 10 , and R 11 are independently alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroalkyl, where R 9 , R 10 , and R 11 are optionally substituted, preferably-substituted with at least one group selected from the group consisting of halo, haloalkyl, alkoxy, and thiohaloalkyl; or where R 9 and R 10 taken together with the nitrogen to which they are attached form a heterocyclic ring comprising at least one heteroatom selected from N, O and S;

and all pharmaceutically acceptable salts, and geometric isomers thereof.

2. A compound of claim 1 , wherein the saccharide portion is

3. A synthetic compound selected from the group consisting of:

and all pharmaceutically acceptable salts, and geometric isomers thereof.

4. A synthetic compound having a formula selected from the group consisting of:

and all pharmaceutically acceptable salts, and geometric isomers thereof.

5. A synthetic compound having the formula:

and all pharmaceutically acceptable salts, and geometric isomers thereof.

6. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising the compound according to claim 4 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising the compound according to claim 5 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2019
From: SENEB BIOSCIENCES, INC.
To: LA JOLLA PHARMACEUTICAL COMPANY
Reel/Frame 048121/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2009
From: NEOSE TECHNOLOGIES, INC.
To: SENEB BIOSCIENCES, INC.
Reel/Frame 023348/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2004
From: DEFREES, SHAWN; GUANG-WANG, ZHI
To: NEOSE TECHNOLOGIES, INC.
Reel/Frame 015840/0746 →